Advances in pharmacotherapy for tobacco dependence

Expert Opinion on Emerging Drugs

Volumn 9, Issue 1, 2004, Pages 39-53

  Foulds, Jonathan ^a,b   Burke, Michael ^a   Steinberg, Michael ^a,b   Williams, Jill M ^a,b   Ziedonis, Douglas M ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cessation; Dependence; Nicotine; Pharmacotherapy; Smoking; Tobacco; Treatment

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACCOMPLIA; AMFEBUTAMONE; ANXIOLYTIC AGENT; BROMOCRIPTINE; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; CLONIDINE; CYTISINE; GLUCOSE; MECAMYLAMINE; MOCLOBEMIDE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE TARTRATE; NICOTINE VACCINE; NORTRIPTYLINE; REBOXETINE; RIMONABANT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TA NIC; TABEX; UNCLASSIFIED DRUG; VACCINE; VARENICLINE;

BEHAVIOR THERAPY; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NERVOUSNESS; NICOTINE REPLACEMENT THERAPY; NONHUMAN; REVIEW; SEIZURE; SIDE EFFECT; SMOKELESS TOBACCO; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT INDICATION; XEROSTOMIA;

ANIMALS; BLOOD-BRAIN BARRIER; CLINICAL TRIALS; COMBINED MODALITY THERAPY; COMORBIDITY; DRUG ADMINISTRATION ROUTES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HEALTH EDUCATION; HUMANS; MARKETING; MENTAL DISORDERS; NICOTINE; NICOTINIC ANTAGONISTS; RATS; SMOKING; SMOKING CESSATION; SOCIAL SUPPORT; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER; VACCINES;

EID: 2642580863     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.9.1.39     Document Type: Review

References (82)

1. DEPARTMENT OF HEALTH AND HUMAN SERVICES: Reducing Tobacco use: A Report of the Surgeon General Atlanta (GA). US Department of Health and Human Services, Office on Smoking and Health. (2000).
2. ROYAL COLLEGE OF PHYSICIANS: Nicotine Addiction in Britain: A Report of the Advisory Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians of London, London (2000).
3. THE WORLD BANK: Curbing the Epidemic: Governments and the Economics of Tobacco Control The International Bank for Reconstruction and Development/The World Bank, Washington DC, USA (1999).
4. FIORE MC, BAILEY WC, COHEN SJ et al.: Treating Tobacco Use and Dependence: Clinical Practice Guideline. US Department of Health and Human Services, Public Health Service, Rockville, MD, USA (2000).
5. HUGHES JR, KEELY J, NAUD S: Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction (2004) 99(1):29-38.
6. WORLD HEALTH ORGANIZATION: International Statistical Classification of Diseases and Related Health Problems (10th revision). WHO, Geneva (1992).
7. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th edition). American Psychiatric Association, Washington, USA (1995).
8. SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2002) (4):CD000146.
9. HAJEK P, WEST R, FOULDS J, NILSSON F, BURROWS S, MEADOWS A: Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. (1999) 159(17):2033-2038.
10. WEST R, HAJEK P, FOULDS J, NILSSON F, BURROWS S, MEADOWS A: A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (2000) 149:198-202.
11. HUGHES JR, STEAD LF, LANCASTER T: Antidepressants for smoking cessation. Cochrane Database Syst. Rev. (2003) (1):CD000031.
12. CRYAN JF, GASPARINI F, VAN HEEKE G, MARKOU ATHINA: Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond buproprion. Drug Discov. Today (2003) 8(22):1025-1034.
13. GEORGE TP, O'MALLEY SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. (2004) 25(1):42-48. Good recent review of pharmacological treatments.
14. BURTON SL, GITCHELL JG, SHIFFMAN S: Use of FDA-approved pharmacologic treatments for tobacco dependence - United States, 1984-1998. Morb. Mortal Wkly Rep. (2000) 49(29):665-668.
15. MCNEILL A, FOULDS J, BATES C: Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction (2001) 96:1757-1768. Good critique of current regulations for nicotine replacement therapies.
16. HAJEK P, JARVIS MJ, BELCHER M, SUTHERLAND G, FEYERABEND C: Effect of smoke-free cigarettes on 24 h cigarette withdrawal: a double blind placebo-controlled study. Psychopharmacology (Berl.) (1989) 97(1):99-102.
17. FOULDS J, RAMSTROM L, BURKE M, FAGERSTROM K: The effect of smokeless tobacco (snus) on public health in Sweden. Tob. Control (2003) 12:349-359.
18. BENOWITZ NL: Snuff, nicotine and cardiovascular disease: implications for tobacco control. J. Am. Coll. Cardiol. (1999) 34(6):1791-1793.
19. BENOWITZ NL, JACOB P 3rd: Effect of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin. Pharmacol. Ther. (2000) 67(6):653-659.
20. FOWLERJS, LOGAN J, WANG GJ, VOLKOV ND: Monoamine oxidase and cigarette smoking. Neurotoxicology (2003) 24(1):75-82.
21. ROSE JE, BEHM FM, RAMSEY C, RITCHIE JC: Platelet monoamine oxidase, smoking cessation and tobacco withdrawal symptoms. Nicotine Tob. Res. (2001) 3:383-390.
22. GOURLAY SG, STEAD LF, BENOWITZ NL: Clonidine for smoking cessation. Cochrane Database Syst. Rev. (2000) (2):CD000058.
23. SHYTLE RD, PENNY E, SILVER AA, GOLDMAN J, SANBERG PR: Mecamylamine (Inversine): an old antihypertensive with new research directions. J. Hum. Hypertens. (2002) 16(7):453-457.
24. WEST R: Glucose for smoking cessation: does it have a role? CNS Drugs (2001) 15(4):261-265.
25. BERLIN I, SAID S, SPREUX-VAROQUAUX O et al.: A reversible monoamine oxidase a inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. (1995) 58(4):444-452.
26. DAVID S, LANCASTER T, STEAD LF: Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. (2001) (3):CD003086.
27. BIBERMAN R, NEUMANN R, KATZIR I, GERBER Y: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction (2003) 98(10):1403-1407. Promising results from selegiline in this trial.
28. HUGHES JR, STEAD LF, LANCASTER T: Anxiolytics for smoking cessation. Cochrane Database Syst. Rev. (2000) (4):CD002849.
29. Pfizer unveils anti-smoking drug. Wall Street Journal (2003).
30. SLATER YE, HOULIHAN LM, MASKELL PD et al.: Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology (2003) 44(4):503-515.
31. KEM WR: The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav. Brain Res. (2000) 113(1-2):169-181.
32. KITAGAWA H, TAKENOUCHI T, AZUMA R et al.: Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology (2003) 28(3):542-551.
33. GROTTICK AJ, TRUBE G, CORRIGALL WA et al.: Evidence that nicotine alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther. (2000) 294(3):1112-1119.
34. MARKOU A, PATERSON NE: The nicotine antagonist mathyllcacotinine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob. Res. (2001) 3(4):361-373.
35. LAVIOLETTE SR, VAN DER KOOY D: The motivational valence of nicotine in the rat tegmental area is switched from rewarding to aversive following blockade of the alpha-7 subunit-containing nicotine acetylcholorine. Psychopharmacology (2003) 166(3):306-313.
36. LAVIOLETTE SP, VAN DER KOOY D: The neurobiology of nicotine addiction: bridging the gap from molecules to behavior. Nat. Rev. Neurosci. (2003) 166(3):306-313.
37. MURPHY MF, HEY K, JOHNSTONE E: Bromocriptine use is associated with decreased smoking rates. Addict. Biol. (2002) 7(3):325-328.
38. JARVIK ME, CASKEY NH, WIRSHING WC: Bromocriptine reduces cigarette smoking. Addiction (2000) 95(8):1173-1183.
39. GEORGE TP, VESSICCHIO JC, TERMINE A: A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Psychiatry (2003) 53(2):136-143.
40. MILLER DK, WONG EH, CHESNUT MD, DWOSKIN LP: Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. (2002) 302(2):687-695.
41. RAUHUT AS, MULLINS SN, DWOSKIN LP, BARDO MT: Reboxetine: attenuation of intravenous nicotine self-administration in rats. J. Pharmacol. Exp. Ther. (2002) 303 (2):664-672.
42. KLIMEK V, ZHU MY, DILLEY G et al.: Effects of long-term cigarette smoking on the human locus coeruleus. Arch. Gen. Psychiatry (2001) 58:821-827.
43. EPSTEIN AM, KING AC: Naltrexone attenuates acute cigarette smoking behavior. Pharmacol. Biochem. Behav. (2004) 77(1):29-37.
44. COHEN C, PERRAULT G, VOLTZ C, STEINBERG R, SOUBRIE P: SR141716A, a central cannabinoid receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. (2002) 13:451-463.
45. TZAVARA EY, DAVIS RJ, PERRY KW et al.: The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. (2003) 138:544-553.
46. ANTHENELLI RM, DESPRES JP: Effects of Rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit). American College of Cardiology 53rd Annual Scientific Session, New Orleans, LA, USA (2004).
47. WEST R, WILLIS N: Double-blind placebo controlled trial of dextrose tablets and nicotine patch in smoking cessation. Psychopharmacology (Berl.) (1998) 136(2):201-204.
48. WEST R, COURTS S, BEHARRY S, MAY S, HAJEK P: Acute effect of glucose tablets on desire to smoke. Psychopharmacology (Berl.) (1999) 147(3):319-321. Impressive results from oral glucose in this trial.
49. MCROBBIE H, HAJEK P: Effect of glucose on tobacco withdrawal symptoms in recent quitters using brupopion or nicotine replacement. Hum. Psychopharmacol. (2004) 19:57-61.
50. HARAKAS P, FOULDS J: Acute effects of glucose tablets on craving, withdrawal symptoms, and sustained attention in 12-h abstinent tobacco smokers. Psychopharmacology (Berl.) (2002) 161(3):271-277.
51. WEST R: Glucose therapy: role and efficacy. Italian Society of Pulmonary Medicine, Rome (2003).
52. SHIFFMAN S, FANT RV, GITCHELL JG et al.: Nicotine delivery systems: how far has technology come? Am. J. Drug Deliv. (2003) 1(2):112-124.
53. D'ORLANDO K, FOX B: Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw a novel nicotine replacement product. Nicotine Tob. Res. (2004) 6:63-70.
54. RUSSELL MAH, JARVIS MH, FEYERBRAND C, FERNO O: Nasal nicotine solution: a potential aid to giving up smoking? Br. Med. J. (1983) 286:683-684.
55. FANT RV, HENNINGFIELD JE, SHIFFMAN S, STRAHS KR, REITBERG DP: A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol. Biochem. Behav. (2000) 67:479-482.
56. MCNEIL CONSUMER HEALTHCARE: Nicotrol Inhaler: mean nicotine concentrations after a 1 mg dose of nicotrol NS (=30). Physician's Desk Reference (2001) 55:1828.
57. WESTMAN EC, TOMLIN KF, PERKINS CE: Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob. Research (2001) 3:391-396.
58. PARK CR, MUNDAY DL: Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int. J. Pharm. (2002) 237:215-226.
59. NIAURA R, SAYETTE M, SHIFFMAN S et al.: Comparative efficacy of rapid-release nicotine gum versus nicorette in relieving smoking cue-provoked craving. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA, USA (2003).
60. FOULDS J, RUSSELL MAH, JARVIS MJ, FEYERABEND C: Nicotine absorption and dependence in unlicensed lozenges available over the counter. Addiction (1998) 93:1427-1431.
61. HUGHES JR, LESMES GR, HARSUKAMI DK et al.: Are higher doses of nicotine replacement more effective for smoking cessation. Nicotine Tob. Res. (1999) 1:169-174.
62. JORENBY DE, SMITH SS, FIORE MC et al.: Varying nicotine patch dose and type of smoking cessation counseling. JAMA (1995) 274:1347-1352.
63. TONNESEN P, PAOLETTI P, GUSTAVSSON G et al.: Higher dosage nicotine patches increase one-year smoking cessation rates; results from the Collaborative European Anti-Smoking Evaluation (CEASE) trial. Eur. Respir. J. (1999) 13:238-246.
64. SWEENEY CT, FANT RV, FAGERSTROM KO et al.: Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs (2001) 15:453-467.
65. FAGERSTROM KO, SCHNEIDER NG, LUNELL E: Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for nicotine withdrawal symptoms. Psychopharmacology (Berl.) (1993) 111:271-277.
66. WENNIKE P, DANIELSSON T, LANDFELDT B et al.: Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction (2003) 98(10):1395-1402.
67. LASSER K, BOYD JW, WOOLHANDLER S, HIMMESTEIN DU, MCCORMICK D, BOR DH: Smoking and mental illness: A population-based prevalence study. JAMA (2000) 284:2606-2610.
68. GEORGE TP, ZIEDONIS DM, FEINGOLD A et al.: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am. J. Psychiatry (2000) 157(11):1835-1842.
69. LERMAN C, NIURA R: Applying genetic approaches to the treatment of nicotine dependence. Oncogene (2002) 21:7412-7420 Good review of genetic approaches to nicotine dependence.
70. PENTEL PR, MALIN DH, ENNIFAR S et al.: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats; Pharmacol. Bioch. Behav. (2000) 65(1):191-198.
71. SATOSKAR SD, KEYLER DE, LESAGE MG: Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int. Immunopharmacol. (2003) 3:957-970.
72. FOX BS, KANTAK KM, EDWARDS MA et al.: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. (1996) 2:1129-1132.
73. CLAIR-ROBERT J, AKERS CVR, VANHINSBERGH L, MCKENNA KA, WOOD DM, JACK L: Longitudinal safety and immunogenicity data of TA-NIC, a novel nicotine vaccine. Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, LA, USA (2003) (Abstract).
74. LINDMAYER K, HORWITH G, FATTOM A et al.: Results of a Phase I, double-blinded, controlled safety and immunogenicity trial of NICVAX, a conjugated nicotine vaccine. Society for Research on Nicotine and 9th Annual Meeting, New Orleans, LA, USA (2003) (Abstract).
75. SLOTKIN TA: Fetal nicotine or cocaine exposure; which one is worse? J. Pharmacol. Exp. Ther. (1998) 285(3):931-945.
76. KEYLER DE, SHOEMAN D, LESARGE MG, CALVIN AD, PENTEL PR: Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J. Pharmacol. Exp. Ther. (2003) 305(2):587-592.
77. STEAD LF, LANCASTER T: Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev. (2002) (3):CD001007.
78. STEAD LF, LANCASTER T, PERERA R: Telephone counseling for smoking cessation. Cochrane Database Syst. Rev. (2003) (1):CD002850.
79. MACLEOD ZR, CHARLES MA, ARNALDI VC, ADAMS IM: Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial. Med. J. Aust. (2003) 179(7):349-352.
80. RIGOTFI NA, MUNAFO MR, MURPHY MF, STEAD LF: Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst. Rev. (2003) (1):CD001837.
81. ZIEDONIS DM, GEORGE TP: Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr. Bull. (1997) 23(2):247-254.
82. HALL SM, REUS VI, MUNOZ RF et al.: Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry (1998) 55(8):683-690.